A study evaluating the safety and efficacy of Debio 4326 in treating precocious puberty in children receiving gonadotropin-releasing hormone agonist
Full IRB Study Title:
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)
IRB Study ID: 2024-051
Please view the study at Clinicaltrials.gov for complete information.
Study Sponsor:
Debiopharm International S.A
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Naveen Uli, MD - Phone: 330-543-3276; email: nuli@akronchildrens.org
JoAnn Katz, BSN – Phone: 330-543-0690; email: jkatz@akronchildrens.org
Lead Investigator
Naveen Uli, MD
Medical Director, Center for Diabetes and Endocrinology; Pediatric Endocrinologist
